Garret Seiler, DO
Infectious Disease · Wichita, KSNPI 1255789566
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,625 of the $1,844 with a category attached, or 88.1%. It is spread thinly across 19 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations.
Across 80 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$251
- Astellas Pharma US Inc$227
- AbbVie$168
- Insmed, Inc.$157
- Tetraphase Pharmaceuticals, Inc.$132
- Takeda Pharmaceuticals U.S.A., Inc.$127
- plus $781 from 13 others
What the payments were for
- Consulting fees$211%
- Food & beverage$1,62588%
- Education$19811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 5 | $251 |
| Astellas Pharma US Inc | 4 | $227 |
| AbbVie | 10 | $168 |
| Insmed, Inc. | 10 | $157 |
| Tetraphase Pharmaceuticals, Inc. | 7 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $127 |
| Melinta Therapeutics, LLC | 6 | $108 |
| Paratek Pharmaceuticals, Inc. | 5 | $103 |
| Hospira, Inc. | 5 | $91 |
| Ferring Pharmaceuticals Inc. | 2 | $86 |
| Merck | 6 | $84 |
| Shionogi Inc | 4 | $80 |
| Grifols USA, LLC | 2 | $49 |
| ADMA Biomanufacturing LLC | 2 | $41 |
| Tersera Therapeutics LLC | 2 | $40 |
| Viiv Healthcare Company | 2 | $40 |
| Mayne Pharma Commercial LLC | 1 | $28 |
| Convatec Inc. | 1 | $16 |
| Octapharma USA, Inc. | 1 | $14 |
How this compares
$1,844 in reported general payments places this provider in the 80th percentile of 56 infectious disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 29 | $10,126 |
| ErtapenemErtapenem Sodium | 18 | $9,010 |
| Lopinavir-RitonavirLopinavir/Ritonavir | 11 | $8,443 |
| Rifabutin | 17 | $5,353 |
| Posaconazole | 13 | $5,084 |
| CefepimeCefepime In Iso-Osm Dextrose | 11 | $3,638 |
| CeftriaxoneCeftriaxone Sodium | 25 | $2,903 |
| Minocycline Hcl | 58 | $1,941 |
| Fluconazole | 14 | $1,855 |
| Vancomycin Hcl | 18 | $1,605 |
| Linezolid | 11 | $1,394 |
| Methenamine Hippurate | 31 | $1,364 |
| Moxifloxacin Hcl | 13 | $1,306 |
| Cephalexin | 69 | $1,173 |
| Ethambutol Hcl | 22 | $869 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Wichita
- Thomas MooreWichita$37K
- Maha AssiWichita$9K
- Margaret HaganWichita$4K
- Keck HartmanWichita$2K
- Jerry PeterieWichita$2K
- Shelley JonesWichita$2K
- Wissam El AtrouniKansas City$15K
- John FriedOverland Park$7K
- Marjorie WongskhaluangLeawood$5K
- Apoorv KalraOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.